Table 2.
Disease | Changes of MPO | Matrix | Method | Ref. |
---|---|---|---|---|
Arthritis | ||||
| ||||
Rheumatoid arthritis | Increased activity/concentration | SF | ELISA | [120] |
Increased concentration | Serum | ELISA | [121] | |
Plasma, SF | ELISA | [122] | ||
Increased activity | SF | NMR | [123] | |
| ||||
Juvenile idiopathic arthritis | Increased concentration | Serum | Serum | [124] |
Plasma | ELISA | [125] | ||
| ||||
Atherosclerosis | ||||
| ||||
Increased concentration | Plasma | ELISA | [126] | |
Mixed with lipoproteins | ELISA | [127] | ||
AP | IHC; western blot | [128] | ||
HPLC, western blot | [129] | |||
Increased release by culprit plaque samples | CP | ELISA | [130] | |
Increased activity | AP | Spectrophotometry | [131] | |
| ||||
Diabetes | ||||
| ||||
Increased level | Serum | Spectrophotometry | [132] | |
Increased activity at higher G allele, anti-inflammatory effect of mutant A allele | MPO -463 G/A SNP | PCR | [133] | |
Increased concentration | Plasma | ELISA | [134] | |
Decreased activity | Neutrophilic cell lysate | Spectrophotometry | [135] | |
| ||||
Neurodegenerative diseases | ||||
| ||||
Alzheimer's disease | Increased concentration | Plasma | ELISA | [136] |
Expression | Astrocytes | Confocal microscopy, IHC | [137] | |
Increased Expression | Brain tissue | Immunoblot, IHC, PCR | [138] | |
| ||||
Parkinson's disease | Expression | Brain tissue | IHC | [139] |
| ||||
Multiple sclerosis | Increased activity/concentration | Cerebral Cortex | Colorimetric analysis | [140] |
Expression | Microglia | IHC | [141] | |
| ||||
Systemic lupus erythematosus | ||||
| ||||
Increased concentration | Serum | ELISA | [121] | |
Plasma | ELISA | [142] | ||
| ||||
Lung diseases | ||||
| ||||
Acute pulmonary tuberculosis | Increased concentration | Serum | EIA | [143] |
| ||||
COPD | Increased levels | Sputum | Meta-analysis | [144] |
ELISA | [145, 146] | |||
| ||||
Cystic fibrosis | Increased concentration | Sputum | ELISA | [147] |
SF, synovial fluid; AP, atherosclerotic plaque; COPD, chronic obstructive pulmonary disease; CP, culprit plaque; EIA, Enzyme Immunoassay; ELISA, Enzyme-Linked Immunosorbent Assay; HPLC, High Performance Liquid Chromatography; IHC, immunohistochemistry; NMR, Nuclear Magnetic Resonance; SNP, Single Nucleotide Polymorphism.